Lilly(US:LLY) Benzinga·2026-01-14 20:02Company Overview - Eli Lilly and Co is a pharmaceutical company focusing on neuroscience, cardiometabolic diseases, cancer, and immunology. Key products include Verzenio for cancer, Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic conditions, and Taltz and Olumiant for immunology [8]. Current Market Status - The current market price of Eli Lilly (LLY) is $1,069.3, reflecting a decrease of 0.73%. The stock has a trading volume of 1,133,591. RSI indicators suggest that the stock may be approaching overbought conditions. The next earnings report is expected in 21 days [10]. - Market experts have issued ratings for Eli Lilly, with a consensus target price set at $1,250. An analyst from UBS has downgraded the stock to a Buy rating with the same price target [9]. Options Trading Insights - Recent options trading activity indicates a bearish sentiment among large investors, with 45% of trades being bearish and 35% bullish. A total of 120 uncommon options trades were detected, with 39 puts amounting to $1,794,386 and 81 calls totaling $4,052,883 [2][3]. - The significant investors are targeting a price range for Eli Lilly between $610.0 and $1,660.0 over the past three months [3]. - The mean open interest for Eli Lilly options trades is 387.99, with a total volume of 2,219.00 [4].